Known safety concerns, contraindications, and risk factors.
BPC-157, Semax, Dihexa, Selank, and Cerebrolysin are not FDA-approved for any indication at time of writing. BPC-157 is currently under evaluation for potential Category 1 reclassification, with a PCAC review scheduled for July 23, 2026. All compounds must be sourced from licensed compounding pharmacies with a valid physician's prescription. This protocol is not medical advice, not a prescription, and not a recommendation to self-administer any substance. The majority of supporting data comes from animal models — large-scale human clinical trials are absent for most neuro-regenerative indications. If you choose to use any of these compounds, do so with qualified medical supervision, pharmaceutical-grade sourcing, and full awareness of the legal status in your jurisdiction.
Personal history of malignant tumors or active malignancy
BPC-157's pro-angiogenic mechanism and Dihexa's HGF/c-Met pathway activation both carry theoretical risk of promoting tumor growth and metastasis.
Epilepsy or seizure disorder
Contraindicated due to potential for unpredictable neuro-excitability from dopaminergic modulation.
History of myocardial infarction, unstable angina, or uncontrolled hypertension
Cardiovascular history triggers a high-risk warning due to the angiogenic and vasomotor effects of BPC-157.
Hepatic impairment
Avoid due to lack of clearance data for BPC-157 and adjacent peptides in hepatic dysfunction.
Severe psychiatric disorders (severe anxiety, manic episodes)
Semax is specifically contraindicated in severe psychiatric disorders as it may exacerbate these conditions via dopaminergic and serotonergic modulation.
Pregnancy or breastfeeding
Due to a complete lack of research in these populations, all experimental peptides in this class are contraindicated during pregnancy and breastfeeding.
Concurrent NSAID use during active healing cycle
NSAIDs' anti-inflammatory mechanism may interfere with BPC-157's upstream regenerative signaling during tissue healing or neuroregeneration.
Concurrent use of SSRIs, MAOIs, or antipsychotics with Semax
Semax interacts with the dopaminergic and serotonergic systems; combining it with psychotropic medications may lead to amplified or unpredictable side effects.
Competitive athletes under WADA jurisdiction
BPC-157 is classified as a non-approved substance by WADA and is prohibited for use by competitive athletes.